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ABSTRACT 
Objective: Neuropathic pain arises from demage, or the pathological changes in the peripheral or central nervous system. The pain is difficult to 
treat as standard treatment with conventional analgesics doesn`t typically provide effective relief of pain. 
Methods: It was a one year study of utilization and analysis of prescriptions for PNDs (Painful neuropathic disorders). The parameters evaluated 
were demographic profile of the patient (age and gender), type and etiology of PNDs, drug data (name of the group of drugs with individual drugs, 
mono or polytherapy, number of drugs per prescription, formulation) and associated adverse drug reactions(ADR) with the prescribed drug. 
Results: Maximum number of patients of PNDs resides in the age group of 18 – 35 yrs (41.2%) & more common in females. The most common PND 
encountered was painful diabetic neuropathy (43.9%) followed by cervical and lumbar radiculopathy, post herpetic neuralgia. 2942 drugs were 
prescribed in 1020 prescriptions out of which, 96.8% were oral and 3.2% were topical formulations. Most frequently prescribed group of drug was 
tricyclic antidepressant (27.3%) followed by anticonvulsants (25.3%). Polypharmacy was seen 89.7% as compared to monotherapy (10.3%). Only 
132 ADRs of various types were seen. The most common organ system affected was central nervous system followed by gastro intestinal systems. 
The most common drugs implicated for ADRs were TCAs (24.4%), anticonvulsants (16.6%), and Pregabeline (9.8%). There were no fatal adverse 
events. Mild to moderate ADRs included constipation, nausea, vomiting, drowsiness, dryness of mouth.  
Conclusions: The choice of drug depends on etiology of neuropathic pain, drug efficacy and availability and also on ADR profile. 
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INTRODUCTION 
Neuropathic pain is a type of pain which is either arising as a direct 
consequence of a lesion (dysfunction of either the peripheral nerves 
or, less commonly, the central nervous system) or a disease affecting 
the somatosensory system [1 – 3]. 
The nervous system is broadly classified into central and peripheral 
nervous system, and lesions of various etiologies affecting either system 
can lead to neuropathic pain. The common neuropathic conditions 
affecting the peripheral nervous system include peripheral diabetic 
neuropathic pain (PDPN), post-herpetic neuralgia (PHN), AIDS 
polyneuropathy, cervical or lumbar radiculopathy, mechanical 
compression such as entrapment syndromes (e. g. Carpal tunnel 
syndrome), Hansen’s neuropathy, phantom limb pain after amputation, 
trigeminal neuralgia and traumatic nerve injury etc. Central causes for 
neuropathic pain include spinal cord injury (SCI), multiple sclerosis (MS) 
and stroke leading to central post-stroke pain (CPSP). 
PNDs are difficult to treat, and often require treatment with antiepileptic 
drugs (AEDs) and/or tricyclic antidepressants (TCAs) instead of addition 
of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids (agents 
that are used to treat nociceptive pain). Guidelines for the treatment of 
painful neuropathies that was recommended previously was a stepwise 
approach with TCAs and/or AEDs used initially, followed by other agents 
(e. g., duloxetine, opioids) if required. If the pain persists due to 
inadequate control with drugs, they are recommended to attend pain 
clinics and/or psychological support [4]. Currently, the different 
categories of drugs that are recommended for management of painful 
neuropathies are TCAs, selected AEDs (i. e., Gabapentin, Pregabalin, 
Carbamazepine), serotonin-norepinephrine reuptake inhibitor (SNRI), 
antidepressants (i. e., duloxetine, Venlafaxine), and topical Lidocaine 
(Lignocaine) as first- and/or second-line therapy for pharmacological 
management; Tramadol and other Opioids are now recommended as 
second- and/or third-line therapy [5,6]. Patients’ quality of life (both 
physical and emotional functioning) is mostly affected by painful 
neuropathic disorders (PNDs) [7 – 11] which is in turn responsible for 
substantial social stigma to the patient [11 – 16]. It is being a major 
challenge for the clinician to treat PNDs as it is a type of pain which is 
refractory in nature to the existing treatments. In randomized clinical 
trials (RCTs) it has been seen that no more than half of patients 
experience clinically meaningful pain relief with the available therapy, 
which is almost always partial but not complete relief [7]. Sometimes it is 
seen that patients frequently experience adverse effects to the drugs 
prescribed and due to this there is unsatisfactory patient compliance & 
require proper vigilance to avoid or minimize this. 
A lot of studies have been published regarding the etiology, 
pathophysiology, and treatment of neuropathic pain; relatively little has 
been reported about the pattern of prescription, clinical characteristics 
and demographic profile and adverse effects of drugs used in the 
treatment of patients with PNDs in clinical practice, including their levels 
of use of pain-related pharmacotherapy and healthcare services.  
Aims and objective  
To study the pattern of utilization of drugs for the management of 
PNDs & their related ADR profile. 
MATERIALS AND METHODS 
The study was conducted in the Neurology as well as Paediatric OPD 
in collaboration with the Department of Pharmacology, Department 
of Dermatology in IMS & SUM Hospital, S ‘O’ A University, 
Bhubaneswar, Odisha. It was undertaken for one year from APRIL 
2013 to MARCH 2014. Permission from the institutional ethics 
committee was obtained. Consent was obtained from the patient or 
their guardians. The current study was designed as a cross sectional, 
unicentric drug utilization study and analysis of the prescriptions for 
PNDs. The subjects who had willingly participated were enrolled on 
the basis of inclusion and exclusion criteria. All prescriptions issued 
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during this period were recorded on case record forms. Our study 
was conducted on 1020 patients. All patients with PNDs irrespective 
of age & sex were included in the study. The criteria for including a 
subject in the study were that he/she has been diagnosed to have PNDs 
by a Consultant Neurologist or a paediatrician with a clinical history, 
examination and relevant investigations and consented to take part in 
this study. ADRs were recorded as self reporting method using ADR 
reporting form by CDSCO. 
Parameters for evaluation 
Demographic profile of the patient (age and gender), type and 
etiology of PNDs,  
Drug data (name of the group of drugs with individual drugs, mono 
or polytherapy, number of drugs per prescription, formulation) and 
associated adverse drug reactions with the prescribed drug were 
recorded during this study period. 
RESULTS 
Demographic profile of the patients suffering from PNDs enrolled in 
our study is depicted in table 1. The age ranged from 12 to 83 years 
with maximum percentage in the age group of 18-35(41.2%). 
PNDs were more common in females. Out of a total of 1020 patients, 
37.1% were males and 62.9% were females (Table 1). 
 
Table 1: Demographic profile of patients of Painful neuropathic disorders (n= 1020): 
Characteristic Number of Patients with % 




66 - 80 118(11.5) 
≥ 81 6(0.5) 
Sex Male 378(37.1) 
Female 642(62.9) 
 The most common PNDs encountered was painful diabetic neuropathy (43.9%) followed by cervical and lumbar radiculopathy (10.9 %), post 
herpetic neuralgia (8.6%) and nerve impingement syndromes (6.6%). (Table 2) 
 
Table 2: Distribution of painful neuropathic disorders (n = 1020) 
Painful neuropathic disorder Number of Patients with % 
Diabetic neuropathy 448(43.9) 
Post-herpetic neuralgia 88(8.6) 
Phantom limb pain  6((0.5) 
Cervical or lumbar radiculopathy 112(10.9) 
Neuropathic postoperative pain 65(6.3) 
Trigeminal neuralgia and atypical facial pain 64(6.2) 
Nerve impingement syndromes 68(6.6) 
Alcoholic polyneuropathy 22(2.1) 
AIDS polyneuropathy 8(0.7) 
Post-traumatic neuralgia (such as nerve root compression, post-thoracotomy) 6(0.5) 
Spinal cord injury (SCI) 18(1.7) 
Multiple sclerosis (MS) 4(0.3) 
Stroke leading to central post-stroke pain (CPSP) 64(6.2) 
Hansen neuropathy 27(2.6) 
Neuropathic pain, unspecified 20(1.9) 
The various oral formulations prescribed were TCAs (Amitriptyline, Imipramine, Nortriptyline, Desipramine), SNRIs (Duloxetine Venlafaxine), 
Anticonvulsants (Carbamazepine, Gabapentin, Pregabalin, Lamotrigine, Oxcarbazepine, Topiramte, Valproate), Opioids (Tramadol, Morphine) and 
various topical formulations were Topical lidocaine, Topical capsaicin as listed in the table 3. 
 
Table 3: Neuropathic pain medications 
Medication class/group Dose (mg/d) 
Tricyclic antidepressants 
(amitriptyline,imipramine,nortriptyline,desipramine) 
25 – 150  
SNRIs Duloxetine 60 – 120  
Venlafaxine 150 – 225  
Anticonvulsants 
Carbamazepine 
200 – 1200  
Gabapentin 1200 – 3600  
Pregabalin 150 – 600  
Lamotrigine  200 – 400  
Oxcarbazepine  600 – 1800  
Topiramte  200 – 400  
Valproate  1000 
Opioids 
Tramadol 
200 – 400  
Morphine 15 – 300  
Miscellaneous  
Topical lidocaine  
1 – 3 patches per day applied for 12 hours 
Topical capsaicin 0.025% applied four times a day.  
A total number of 2942 drugs (Table 4) were prescribed in 1020 prescriptions and the average number of drugs per prescription was found to be 
2.88. Out of 2942 drugs prescribed (Table 4), 2848 (96.8%) were oral and 94 (3.2%) were topical formulations. Out of 2848 oral prescriptions, 
tricyclic antidepressant group of drugs 780 (27.3%) was the most frequently prescribed, as compared to anticonvulsants 721 (25.3%). The number 
of fixed dose combination prescribed was 1022. 
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Table 4: Analysis of prescriptions 
Number of prescriptions 1020 
Total no. of drugs prescribed 2942 
Total no. of drugs prescribed through oral route 2848(96.8%) 
Total no. of drugs prescribed through topical route 94 (3.2%) 
Average no. of drugs prescribed per prescription 2.88 
Number of fixed dose combinations 1022(35.8%) 
Amitriptyline 522(66.9%) was the most frequently prescribed antidepressant followed by Nortriptyline 156(20%) and Imipramine 63(8.07%). 
Amongst the anticonvulsants, the most frequently prescribed drug is Pregabalin 464(64.3) followed by Gabapentin 130(18.03). Out of SNRIs, the 
most frequently prescribed drug is Duloxetine 315(60.5) followed by Desvenlafaxine 160(30.7%). Amongst all opioids the most frequently 
prescribed drug is Tramadol 407(88.8) followed by Morphine.(table 5&6) 
 
Table 5: Groups of drugs used for the management of neuropathic pain(n=2848) 
Types of anti neuropathic drugs  Number of drugs used Percentage  
Tricyclic anti-depressants 780 27.3 
SNRIs 520 18.2 
Anti-convulsants 721 25.3 
Opioids  458 16.08 
Miscellaneous  369 12.9 
 
Table 6: Commonly used drugs in the management of neuropathic pain in descending order (n=2848) 
Group of anti neuropathic drugs Name of the drug  Number of drugs prescribed(n=2848) 
Tricyclic anti-depressants (n=780)(27.3%) Amitriptyline  522(66.9) 
Imipramine  63(8.07) 
Nortriptyline  156(20.0) 
Desipramine  39(5.0) 
SNRIs (n=520)(18.2%) Duloxetine 315(60.5) 
Venlafaxine 45(8.6) 
Desvenlafaxine 160(30.7) 
Anti-convulsants (n=721)(25.3%) Carbamazepine 52(7.2) 
Gabapentin 130(18.03) 
Pregabalin 464(64.3) 
Lamotrigine  6(0.83) 
Oxcarbazepine  42(5.8) 
Topiramte  4(0.5) 
Valproate  23(3.1) 
Opioids (n=458)(16.08%) Tramadol 407(88.8) 
Morphine 51(11.2) 
Miscellaneous (n=369)(12.9%) Topical lidocaine  72 
Topical capsaicin 22 
The drugs under miscellaneous groups are NSAIDs, Baclofen, Clonidine, Paroxetine, Citalopram, Bupropion, Polypharmacy was seen in 914 (89.7%) 
prescriptions as compared to 106(10.3%) prescriptions with monotherapy (table 7) 
 
Table 7: Type of prescription (n=1020) 
Type of prescription No. of prescription (%) 
Monotherapy  106(10.3) 
Polytherapy  914(89.7) 
 
 In our study group 116 patients developed 132 ADRs of various 
types. (Table 8). Some patients developed more than one ADR. In 
most of the ADRs, the organ system affected was central nervous 
system followed by gastro intestinal systems. The most common 
drugs implicated for ADRs were TCAs [Most common Amitriptyline; 
32(24.4%)], Anticonvulsants [(Carbamazepine; 22 (16.6%)], and 
Pregabalin 13 (9.8%). Drowsiness, dizziness, Nausea was the 
commonest ADR noted. Dermatological ADRs were commonly seen 
with topical preparations. Causality assessment revealed that 76 
ADRs (57.5%; n=132) were probable category & 56 were in the 
category of possible ADRs according to WHO-UMC criteria. Not a 
single case of ‘certain’ category was noted as rechallenge was not 
attempted by the physician, once a drug was withdrawn.  
There were no fatal adverse events; however two cases of 
orthostatic hypotension with Amitriptyline necessitating 
hospitalization. Mild to moderate ADRs included constipation, 
nausea, vomiting, drowsiness, dryness of mouth and were treated by 
dose adjustment and/or relevant medications to treat the 
symptoms. There was discontinuation of Amitriptyline for weight 
gain, urinary retention & orthostatic hypotension (one case for 
each), lidocaine patch for swelling under patch (2 cases).  
 
Table 8: Drugs for PNDs responsible for ADRs noted: 
Name of the group of 
drugs  
% of ADRs (total no of ADRs = 
132) 
Tricyclic anti-depressants  44(58.08) 






Combination therapy is preferred over monotherapy in case of PND 
management because the combination therapy target different pain 
mechanisms which may be due to its additive or synergistic effects; but 
the evidence, supporting this is less developed [17]. Previous studies 
only focused on monotherapy rather than sequential or parallel 
combinations. There is also less studies published regarding the 
peripheral neuropathic pain in comparison to central neuropathic pain. 
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In our study maximum percentage of PNDs were seen in the age 
group of 18-35(41.2%) and more common in females (62.9%). It 
was described in some studies that the incidence of post herpetic 
neuralgia, painful diabetic neuropathy, phantom limb pain increased 
with age & also depend on severity of the underlying condition [19, 
20]. Phantom limb pain was more common in men than women, 
while post-herpetic neuralgia was more common in women [18]. 
 
Table 9: Adverse drug reaction profile of drugs used in the 






Drowsiness, Confusion, Dry mouth, Orthostatic 
hypotension, Weight gain, Urinary symptoms 
SNRIs  Nausea, Dizziness, Dry mouth 
Anti-
convulsants 
Nausea, Dizziness, Drowsiness 
Opioids Constipation, Dizziness, Drowsiness 
Miscellaneous Skin reactions (such as redness or swelling under 
patch, erythema) 
 
The most common PND encountered during our study period was 
painful diabetic neuropathy (43.9%) followed by cervical and 
lumbar radiculopathy (10.9 %), post herpetic neuralgia (8.6%) and 
nerve impingement syndromes (6.6%) which is contrasting to the 
study of Hall GC et al which showed that post-herpetic neuralgia was 
the most common cause of PNDs followed by trigeminal neuralgia & 
painful diabetic neuropathy [21]. 
Chronic neuropathic pain is a common late complication of leprosy. 
Its diagnosis is made when patient complaints of pain after 
completion of MDT and in the absence of any reaction or new nerve 
impairment. It presents as continuous burning type of pain with 
glove and stocking distribution [22, 23].  
Paediatric neuropathic pain related studies are minimal due to the fact 
that the most common neuropathic pain conditions seen in adults are 
rare in children. For example, among children having diabetes are do 
not progress to the point at which neuropathy is considered as a risk. 
Incidence of postherpetic neuralgia, trigeminal neuralgia, 
radiculopathies, and complications of stroke are rare in children & 
adolescent populations. But in comparison to adult neuropathies, 
there is some peculiar neuropathies are there which is having 
specificity toward paediatric populations such as complex regional 
pain syndromes (CRPSs), phantom limb pain, spinal cord injury, 
trauma and postoperative neuropathic pain, autoimmune and 
degenerative neuropathies (e. g. Guillain-Barre syndrome, Charcot-
Marie-Tooth disease), and the effects of cancer disease processes and 
treatment. There is also some rare neuropathic pain syndromes are 
seen which are relatively unique to the pediatric population, including 
toxic and metabolic neuropathies (eg, lead, mercury, alcohol, and 
infection), hereditary neurodegenerative disorders (e. g. Fabry 
disease), mitochondrial disorders, and primary erythromelalgia [24]. 
A total number of 2942 drugs were prescribed among which 96.8% 
were oral and 3.2% were topical formulations and the average 
number of drugs per prescription was found to be 2.88. Tricyclic 
antidepressant was most commonly prescribed group of drugs 
(27.3%) followed by anticonvulsants (25.3%). TCAs have long been 
used as most commonly prescribed drug in all types of neuropathic 
pain [25]. Analgesic actions may be attributable to noradrenaline 
and serotonin reuptake blockade (presumably enhancing 
descending inhibition), NMDA-receptor antagonism and sodium-
channel blockade [26]. Amitriptyline (66.9%) was the most 
frequently prescribed antidepressant followed by Nortriptyline 
156(20%) and Imipramine 63(8.07%) which is in contrast to a study 
showing secondary amine tricyclic antidepressants (Nortriptyline 
and Desipramine) are better tolerated than tertiary amine tricyclic 
antidepressants (Amitriptyline, Imipramine, Clomipramine) so more 
prescribed [27]. Amongst the anticonvulsants, the most frequently 
prescribed drug is Pregabalin (64.3) followed by Gabapentin 
(18.03). Till now it was seen that in various previous studies, 
carbamazepine remains the most frequently used anticonvulsant for 
neuropathic pain [28]. It has long been appreciated that there a 
similarities between epilepsy and neuropathic pain (in 1885 
Trousseau described trigeminal neuralgia as "epileptiform neuralgia 
[29] and that drugs that are effective in reducing seizure frequency 
may also have an analgesic effect in neuropathic pain [30, 
31].Gabapentin was also frequently prescribed as a first-line 
treatment in the painful diabetic neuropathy and in post-herpetic 
neuralgia, with the use of both gabapentin and Pregabalin increasing 
over the study period. This demonstrates a maintained shift from 
predominant use of opioid and non-opioid analgesics in the late 
1990’s to use of tricyclic antidepressants and antiepileptics, with 
initiation of these therapies now evident in primary, rather than 
secondary, care. Antiepileptic prescribing has moved from 
carbamazepine to gabapentin and Pregabalin, both of which are now 
used more frequently in phantom limb pain. 
Out of SNRIs, the most frequently prescribed drug is Duloxetine 
(60.5%) followed by Desvenlafaxine (30.7%). They have a better 
side effect profile and may therefore be more suitable for elderly 
patients or those with cardiac disease [25] and these drugs may 
soon replace the use of tricyclic antidepressants Amongst all opioids 
the most frequently prescribed drug is Tramadol (88.8) followed by 
Morphine. Opioids can be considered as a first-line approach in 
selected clinical circumstances, such as intractable pain, episodic 
exacerbations of severe pain, acute neuropathic pain, and 
neuropathic cancer pain [32]. The incidence of use of opioids is 
slightly increased due to availability of tramadol as a first-line 
treatment in phantom limb pain [33]. 
According to different studies till date the first line agent in 
treatment of PNDs are antiepileptics and antidepressants and but 
some clinical trials supported the shift from carbamazepine to 
gabapentin, or Pregabalin. The European Federation of Neurological 
Sciences (EFNS) 2010 guidelines recommend gabapentin, 
pregabalin, lidocaine plasters and tricyclic antidepressants in post-
herpetic neuralgia and duloxetine, gabapentin, pregabalin, tricyclic 
antidepressants and venlafaxine in painful diabetic neuropathy [33]. 
The number of fixed dose combination prescribed was 1022. 
Polypharmacy was seen in 89.7%prescriptions as compared to 
10.3% prescriptions with monotherapy. Combination therapy show 
better result at lower doses and with fewer side effects [34]. In a 
recent study it was seen that morphine with gabapentin 
combination was superior to treatment with either drug alone [35]. 
 Another study revealed that gabapentin– venlafaxine combination 
was superior to gabapentin alone [35]. Patients who received more 
than one therapeutic category usually received a mixture of an 
opioid and a non-opioid analgesic rather than combinations with 
demonstrated efficacy in neuropathic pain, such as gabapentin and 
opioids or Nortriptyline [33]. 
In our study group 132 ADRs were encountered only in 116 patients 
of PNDs with various groups of drugs. Some patients developed 
more than one ADR. The most common organ system affected was 
central nervous system and Gastro intestinal systems. The most 
common drugs implicated for ADRs were Amitriptyline (24.4%), 
Carbamazepine (16.6%), and Pregabalin (9.8%). 
In some studies it was seen that tricyclic antidepressants are more 
efficacious than SSRIs & SNRIs but side effect profile are better in 
latter; therefore suitable for elderly patients or those with cardiac 
disease [25]. As systemic side effects are extremely rare with topical 
treatments, they are safe particularly for elderly patients. The most 
common side effects seen with TCAs were anticholinergic side 
effects which can be reduced by starting with low dosages at 
bedtime and dose titration [25, 32]. The most common adverse 
effect of duloxetine is nausea, which seems to be reduced by starting 
with low dose & increasing the dose gradually [36]. SSRIs (e. g.: 
Venlafaxine) was associated with cardiac conduction 
abnormalities,[37] and increases in blood pressure and should be 
tapered due to chance of withdrawal syndrome [38]. 
Gabapentin and Pregabalin are safer drugs with few adverse drug 
reactions such as dose-dependent dizziness and sedation, which can 
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be reduced by low dosage regimen and dose titration [25, 32]. 
Topical drugs show mild local reactions which is becoming 
advantageous in elderly PNDs [25, 32]. 
Constipation, nausea, and sedation are the most common adverse 
effects of opioids necessitating the low dose treatment & dose 
titration. However, constipation tends to be a chronic problem for 
patients taking opioids & should be monitored. The adverse effect 
profile of tramadol is similar to that of opioids, but tramadol also 
lowers the seizure threshold  
CONCLUSION 
Appropriate studies were not published regarding the use of drugs 
in the management of neuropathic pain specifically in paediatric 
population even if many agents may be used in treating neuropathic 
pain. It is the hope of neurologists that the rational use of drugs 
increases the chance of achieving analgesia in patients suffering 
from neuropathic pain. No one therapeutic intervention is 
guaranteed of success.  
Future trials are needed to evaluate optimal drug combinations and 
dose ratios as well as safety, compliance and cost-effectiveness [17]. 
Desired analgesia may be achieved by the pharmacological 
management in most of the patients, but not all, patients. In those 
who fail to respond, in those situations other treatment modalities 
may be considered, ranging from behavior modification and to the 
more major invasive medical techniques. The future aspect of the 
study is that we have the prospect of developing newer additional 
agents which may or may not prove useful analgesics in neuropathic 
pain including agents with more specific sodium channel blocking 
effects, calcium channel blockers and new generation 
anticonvulsants and capitalize on the major expansion in knowledge 
generated from the work of the basic scientists. 
It is hoped that this paper highlights the current outpatient 
therapeutic options and demonstrates a rational approach to the 
management of the patient with neuropathic pain. 
Surgical and chemical sympathectomy has been used to treat 
neuropathic pain.  
Important areas for future research include developing a specific 
diagnostic method for neuropathic pain; identifying associations 
between symptoms, signs, and pathology to guide mechanism based 
treatment strategies; comparing combination treatments with 
monotherapy; and conducting pharmacogenomic studies to guide 
prescribing. 
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